1 |
Wang X, Chen X, Fang J, Yang C (2013). Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. Int J Clin Exp Pathol, 6, 586-97.
|
2 |
Teitz T, Inoue M, Valentine MB, et al (2013). Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. Cancer Res, 73, 4086-97.
DOI
ScienceOn
|
3 |
Tong QS, Zheng LD, Tang ST, et al (2008). Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. World J Pediatr, 4, 58-62.
DOI
|
4 |
Tweddle DA, Pearson AD, Haber M, et al (2003). The p53 pathway and its inactivation in neuroblastoma. Cancer Lett, 197, 93-8.
DOI
ScienceOn
|
5 |
Yamamori M, Sakaeda T, Nakamura T, et al (2004). Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun, 325, 144-50.
DOI
ScienceOn
|
6 |
Pistoia V, Morandi F, Bianchi G, et al (2013). Immunosuppressive microenvironment in neuroblastoma. Front Oncol, 3, 1-8.
|
7 |
Osman J, Galli S, Hanafy M, Tang X, Ahmed A (2013). Identification of novel biomarkers in neuroblastoma associated with the risk for bone marrow metastasis: a pilot study. Clin Transl Oncol, 15, 953-8.
DOI
|
8 |
Owens C, Irwin M (2012). Neuroblastoma: the impact of biology and cooperation leading to personalized treatments. Crit Rev Clin Lab Sci, 49, 85-115.
DOI
ScienceOn
|
9 |
Patterson DM, Gao D, Trahan DN, et al (2011). Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis, 14, 255-66.
DOI
ScienceOn
|
10 |
Remvikos Y, Beuzeboc P, Zajdela A, et al (1989). Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst, 81, 1383-7.
DOI
|
11 |
Sayed-Ahmed MM, Hafez MM, Al-Shabanah OA, et al (2013). Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer. Tumori, 99, 545-54.
DOI
|
12 |
Scholzen T, Gerdes J (2000). The Ki-67 protein: from the known and the unknown. J Cell Physiol, 182, 311-22.
DOI
|
13 |
Shimada H, Ambros IM, Dehner LP, et al (1999). Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer, 86, 349-63.
DOI
|
14 |
Sidell N, Koeffler HP (1988). Modulation of Mr 53,000 protein with induction of differentiation of human neuroblastoma cells. Cancer Res, 48, 2226-30.
|
15 |
Taeb J, Asgari M, Abolhasani M, Farajollahi MM, Madjd Z (2014). Expression of prostate stem cell antigen (PSCA) in prostate cancer: A tissue microarray study of Iranian patients. Pathol Res Pract, 210, 18-23.
DOI
ScienceOn
|
16 |
Meric JB (2007). Angiogenesis targeting in gastro-intestinal cancers. Bull Cancer, 94, 207-15.
|
17 |
Mejia C, Pellin A, Navarro S, Castel V, Llombart-Bosch A (1999). A new mutation of the p53 gene in human neuroblastoma, not correlated with N-myc amplification. Int J Surgical Pathol, 7, 149-54.
DOI
|
18 |
Mehdiabadi GB, Arab E, Rafsanjani KA, Ansari S, Moinzadeh AM (2013). Neuroblastoma in Iran: an experience of 32 years at a referral childrens hospital. Asian Pac J Cancer Prev, 14, 2739-42.
과학기술학회마을
DOI
ScienceOn
|
19 |
Mehrazma M, Madjd Z, Kalantari E, et al (2013). Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: a study using tissue microarray. Fetal Pediatr Pathol, 32, 192-204.
DOI
ScienceOn
|
20 |
Miller CW, Simon K, Aslo A, et al (1992). p53 mutations in human lung tumors. Cancer Res, 52, 1695-8.
|
21 |
Modak S, Cheung NK (2010). Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev, 36, 307-17.
DOI
ScienceOn
|
22 |
Mohsenzadegan M, Madjd Z, Asgari M, et al (2013). Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis. Cancer Immun Immunot, 62, 1609-18.
DOI
ScienceOn
|
23 |
Mueller S, Bhargava S, Molinaro AM, et al (2013). Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer Res, 33, 755-62.
|
24 |
Nikiteas NI, Tzanakis N, Theodoropoulos G, et al (2007). Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. Gastric Cancer, 10, 12-7.
DOI
|
25 |
Jin Q, Hemminki K, Enquist K, et al (2005). Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res, 11, 3647-53.
DOI
ScienceOn
|
26 |
Jakovljevic G, Culic S, Stepan J, Bonevski A, Seiwerth S (2009). Vascular endothelial growth factor in children with neuroblastoma: a retrospective analysis. J Exp Clin Cancer Res, 143, 1-11.
|
27 |
Imamura J, Bartram CR, Berthold F, et al (1993). Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res, 53, 4053-8.
|
28 |
Ishola TA, Chung DH (2007). Neuroblastoma. Surg Oncol, 16, 149-56.
|
29 |
Jonat W, Arnold N (2011). Is the Ki-67 labelling index ready for clinical use? Ann Oncol, 22, 500-2.
DOI
ScienceOn
|
30 |
Levine AJ, Momand J, Finlay CA (1991). The p53 tumour suppressor gene. Nature, 351, 453-6.
DOI
ScienceOn
|
31 |
Maae E, Nielsen M, Steffensen KD, et al (2011). Estimation of immunohistochemical expression of VEGF in ductal carcinomas of the breast. J Histochem Cytochem, 59, 750-60.
DOI
ScienceOn
|
32 |
Madjd Z, Karimi A, Molanae S, Asadi-Lari M (2011). BRCA1 protein expression level and CD44(+) phenotype in breast cancer patients. Cell J, 13, 155-62.
|
33 |
Martin B, Paesmans M, Mascaux C, et al (2004). Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer, 91, 2018-25.
DOI
ScienceOn
|
34 |
Chung YS, Maeda K, Sowa M (1996). Prognostic value of angiogenesis in gastro-intestinal tumours. Eur J Cancer, 32, 2501-5.
DOI
ScienceOn
|
35 |
Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR (1992). Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene, 7, 127-33.
|
36 |
Bukhari MH, Niazi S, Anwar M, Chaudhry NA, Naeem S (2008). Prognostic significance of new immunohistochemistry scoring of p53 protein expression in cutaneous squamous cell carcinoma of mice. Ann N Y Acad Sci, 1138, 1-9.
DOI
ScienceOn
|
37 |
Castel V, Segura V, Berlanga P (2013). Emerging drugs for neuroblastoma. Expert Opin Emerg Drugs, 18, 155-71.
DOI
ScienceOn
|
38 |
Cheung R (2012). Poor treatment outcome of neuroblastoma and other peripheral nerve cell tumors may be related to under usage of radiotherapy and socio-economic disparity: a US SEER data analysis. Asian Pac J Cancer Prev, 13, 4587-91.
과학기술학회마을
DOI
ScienceOn
|
39 |
Del Carmen Mejia M, Navarro S, Pellin A, et al (2002). Study of proliferation and apoptosis in neuroblastoma. Their relation with other prognostic factors. Arch Med Res, 33, 466-72.
DOI
ScienceOn
|
40 |
Ferrara N (2002). VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer, 2, 795-803.
DOI
ScienceOn
|
41 |
Ferrara N, Gerber HP, LeCouter J (2003). The biology of VEGF and its receptors. Nat Med, 9, 669-76.
DOI
ScienceOn
|
42 |
Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991). p53 mutations in human cancers. Science, 253, 49-53.
DOI
|
43 |
Goldhirsch A, Ingle JN, Gelber RD, et al (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 20, 1319-29.
DOI
ScienceOn
|
44 |
Zhang J, Liu Y, Bao P, Wang Y, Zhang Y (2013). Rare coexistence of metastatic neuroblastoma of liver and solid pseudo papillary tumor of pancreas: Case report and literature review. J Cancer Res Ther, 9, 308-10.
DOI
|
45 |
Mejia C, Navarro S, Pellin A, et al (2003). Prognostic significance of cell proliferation in human neuroblastoma: comparison with other prognostic factors. Oncol Rep, 10, 243-7.
|
46 |
Inandiklioglu N, Yilmaz S, Demirhan O, Erdogan S, Tanyeli A (2012). Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma. Asian Pac J Cancer Prev, 13, 5391-7.
과학기술학회마을
DOI
ScienceOn
|